Skip to content
Boca Raton City Online – Lifestyle
Author:
ELI LILLY AND COMPANY
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
March 31, 2026
Lilly’s EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
March 27, 2026
Lilly’s triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
March 19, 2026
Lilly’s EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis
March 16, 2026
Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
March 8, 2026
Patients with Crohn’s disease maintained steroid-free remission for three years with Lilly’s Omvoh (mirikizumab-mrkz)
March 7, 2026
Lilly to participate in TD Cowen’s 46th Annual Health Care Conference
March 6, 2026
USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and Company
March 6, 2026
Lilly’s Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
March 6, 2026
Lilly to acquire Orna Therapeutics to advance cell therapies
March 5, 2026
←
Previous Page
1
2
3
4
Next Page
→